Prabhudas Lilladher initiates Latent View Analytics stock with Buy rating

President Trump has reignited his threat to impose 100% tariffs on movies not made in the United States, claiming that the American film-making industry has been 'stolen' by foreign countries. This move could have significant implications for the film industry, potentially raising costs for consumers and affecting international collaborations.

The Trump administration has implemented stricter export controls targeting Chinese companies, particularly affecting subsidiaries of entities that have been blacklisted by the US government. This move is significant as it reflects ongoing tensions between the US and China, impacting trade relations and potentially hindering the operations of affected companies. The tightening of these controls could lead to further economic repercussions and escalate the trade conflict.

CorVel Corp's stock has reached a 52-week low, dropping to $77.64, which raises concerns among investors about the company's financial health and market performance. This decline could impact investor confidence and may lead to further scrutiny of CorVel's business strategies and future prospects.

Interactive Brokers Group has reached an all-time high stock price of 68.09 USD, marking a significant milestone for the company. This achievement reflects strong investor confidence and robust performance in the financial sector, highlighting the growing interest in online trading platforms. As more investors turn to digital solutions, Interactive Brokers is well-positioned to capitalize on this trend, making it an exciting time for both the company and its shareholders.

Morgan Stanley has significantly raised its price targets and forecasts for HDDs, indicating a strong outlook for the market. This adjustment reflects the firm's confidence in the demand for hard disk drives, which is crucial for various sectors including data storage and cloud computing. Investors and industry stakeholders should pay attention, as these changes could signal growth opportunities and influence market trends.

AstraZeneca is moving forward with plans for a full listing on the US stock market, which is seen as a positive step for the company amid concerns about its potential exit from the UK. This decision not only reassures investors but also highlights AstraZeneca's commitment to maintaining a strong presence in both markets. The dual listing could enhance the company's visibility and access to capital, making it a significant development in the pharmaceutical industry.